NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Forecast & News

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

GRIFOLS S A/S announced a semi-annual dividend on Thursday, October 31st. Shareholders of record on Tuesday, December 3rd will be given a dividend of $0.169 per share on Wednesday, December 11th. This represents a yield of 1.3%. The ex-dividend date of this dividend is Monday, December 2nd. This is an increase from GRIFOLS S A/S's previous semi-annual dividend of $0.15. View GRIFOLS S A/S's Dividend History.

GRIFOLS S A/S's stock split on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were payable to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

GRIFOLS S A/S (NASDAQ:GRFS) posted its earnings results on Tuesday, October, 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.03. The biotechnology company earned $1.46 billion during the quarter, compared to analysts' expectations of $1.39 billion. GRIFOLS S A/S had a return on equity of 13.58% and a net margin of 11.12%. View GRIFOLS S A/S's Earnings History.

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for GRIFOLS S A/S.

5 brokerages have issued 12 month target prices for GRIFOLS S A/S's stock. Their forecasts range from $22.50 to $22.50. On average, they anticipate GRIFOLS S A/S's share price to reach $22.50 in the next year. This suggests that the stock has a possible downside of 5.0%. View Analyst Price Targets for GRIFOLS S A/S.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GRIFOLS S A/S.

Media headlines about GRFS stock have been trending positive on Friday, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for GRIFOLS S A/S.

GRIFOLS S A/S saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,290,000 shares, an increase of 37.6% from the December 15th total of 937,800 shares. Based on an average trading volume of 1,110,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.5% of the company's stock are sold short. View GRIFOLS S A/S's Current Options Chain.

Some companies that are related to GRIFOLS S A/S include Zoetis (ZTS), Allergan (AGN), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY) and GALAPAGOS NV/S (GLPG).

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Teva Pharmaceutical Industries (TEVA), Nektar Therapeutics (NKTR), Southern Copper (SCCO), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Supernus Pharmaceuticals (SUPN), Alibaba Group (BABA) and Novartis (NVS).

GRIFOLS S A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Reilly Financial Advisors LLC (0.05%) and OLD National Bancorp IN (0.00%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including OLD National Bancorp IN.

GRFS stock was acquired by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GRFS stock can currently be purchased for approximately $23.69.

GRIFOLS S A/S has a market capitalization of $16.29 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.17 on an earnings per share basis. GRIFOLS S A/S employs 21,230 workers across the globe.View Additional Information About GRIFOLS S A/S.

The official website for GRIFOLS S A/S is http://www.grifols.com/.

GRIFOLS S A/S's mailing address is 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 212-969-3335 or via email at [email protected]